Treatment and Monitoring of Pernicious Anemia
Patients with pernicious anemia require immediate lifelong vitamin B12 replacement therapy with hydroxocobalamin 1 mg intramuscularly, with the dosing regimen determined by the presence or absence of neurological involvement 1.
Initial Treatment Algorithm
For Patients WITH Neurological Involvement
- Administer hydroxocobalamin 1 mg IM on alternate days until no further improvement occurs
- Then switch to hydroxocobalamin 1 mg IM every 2 months for life 1
- Seek urgent specialist advice from both a neurologist and hematologist when unexplained sensory, motor, or gait symptoms are present 1
Critical pitfall: Neurological damage from B12 deficiency can become irreversible if treatment is delayed. The alternate-day intensive regimen is essential to prevent permanent neurological sequelae 2.
For Patients WITHOUT Neurological Involvement
- Administer hydroxocobalamin 1 mg IM three times weekly for 2 weeks
- Then provide maintenance treatment with 1 mg IM every 2-3 months lifelong 1
Alternative Oral Treatment Option
Oral vitamin B12 at 1000 μg daily is an effective alternative to IM injections and should be offered to patients after informed discussion of both options 3. Oral therapy at this dose provides adequate absorption even in pernicious anemia, despite the intrinsic factor deficiency 3, 4.
Critical Pre-Treatment Consideration
Never initiate folic acid supplementation before treating B12 deficiency 1. Giving folic acid first can mask the underlying B12 deficiency and precipitate subacute combined degeneration of the spinal cord—a potentially irreversible neurological complication. Always check and treat B12 deficiency first.
Monitoring Plan
Assess for Concomitant Deficiencies
Evaluate for iron deficiency in all patients with pernicious anemia, as corpus-predominant atrophic gastritis impairs iron absorption 5. Iron deficiency anemia is common and requires separate treatment.
Screen for Associated Autoimmune Conditions
Screen for autoimmune thyroid disease, as it commonly coexists with autoimmune gastritis 5. Check thyroid function tests and thyroid antibodies.
Endoscopic Surveillance
Patients with newly diagnosed pernicious anemia who have not had recent endoscopy should undergo upper endoscopy with topographical biopsies to:
- Confirm corpus-predominant atrophic gastritis
- Rule out prevalent gastric neoplasia
- Screen for type 1 gastric neuroendocrine tumors 5
Surveillance endoscopy every 3 years should be considered in individuals with advanced atrophic gastritis for gastric cancer risk stratification 5. Small neuroendocrine tumors should be removed endoscopically, followed by surveillance every 1-2 years depending on tumor burden 5.
Laboratory Monitoring
- Monitor hemoglobin and hematocrit to assess treatment response
- Recheck B12 levels after initiating therapy to confirm adequacy of replacement
- The frequency of ongoing laboratory monitoring should be based on clinical response and symptom resolution
Key Clinical Pearls
Pernicious anemia is a late-stage manifestation of autoimmune gastritis characterized by intrinsic factor deficiency leading to B12 malabsorption and macrocytic anemia 5, 6. The underlying autoimmune atrophic gastritis carries long-term risks including gastric adenocarcinoma and neuroendocrine tumors that require ongoing surveillance 6, 7.
The disease often presents insidiously with subtle symptoms, and patients may become acclimatized to their anemia, leading to delayed diagnosis 2. Prompt recognition is vital because neurological complications may become irreversible despite B12 replacement 2.
Diagnostic confirmation can be supported by checking anti-parietal cell antibodies and anti-intrinsic factor antibodies, though intrinsic factor antibodies are the more specific surrogate marker 5, 7.